Israel
PatenSee, with its slogan "Guarding The Lifeline of Dialysis Patients," is a clinical-stage medical device company pioneering a contactless surveillance system for the early detection of asymptomatic vascular stenosis in hemodialysis patients. Leveraging advanced, multi-modal imaging technologies and Machine Learning, PatenSee aspires to flag stenosis risk at the earliest stage, enabling timely interventions to safeguard patients' hemodialysis lifelines, enhance care quality, and extend life expectancy.
Specializing in the health care industry, PatenSee was founded in 2019 in Israel. Notably, the company secured a $750.00KSeed Round investment on 01 April 2019 from MEDX Xelerator, signifying strong support and validation from a prominent healthcare-focused investor.
The potential of PatenSee's solution is underscored by the vast dialysis market, projected to surpass $100B by 2024. Additionally, the company's rapid progression, from inception to first-in-human clinical study in less than two years, reflects strong leadership under CEO Dr. Gal Goshen.
Overall, PatenSee is poised to revolutionize dialysis care, offering investors an opportunity to support a groundbreaking solution with significant market potential and positive societal impact.
